IonQ announced a strategic collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM) to build a quantum-biotech ecosystem focused on advanced therapeutics. The partnership positions IonQ as the core quantum technology provider across CCRM’s global network and builds on IonQ’s recent achievement of 99.99% two-qubit gate fidelity, a world record in quantum computing performance in 2025.
Key points
-
Strategic partnership between IonQ and CCRM to accelerate next-generation therapies using quantum and quantum-AI methods.
-
IonQ becomes the main quantum technology partner for CCRM’s global regenerative medicine network.
-
Focus areas include bioprocess optimization, disease modeling and quantum-enhanced simulations for advanced therapies.
-
IonQ systems recently reached 99.99% two-qubit gate fidelity, setting a world record in 2025.
Background
CCRM operates over 100,000 square feet of GMP facilities and works with hundreds of scientists and partners in regenerative medicine, cell and gene therapy, and biomanufacturing.
IonQ, a leader in trapped-ion quantum computers, has been expanding aggressively in Europe and North America, partnering with organizations like AstraZeneca and establishing innovation hubs in Switzerland and Sweden.
Why this matters
This announcement is important for both quantum and biotech because:
-
It moves quantum computing from “toy problems” to real industrial workloads in drug development and cell therapy.
-
CCRM’s manufacturing and clinical translation expertise meets IonQ’s high-fidelity hardware and quantum-AI stack.
-
The partnership explicitly targets production-grade use cases such as optimizing bioprocesses, designing better disease models, and speeding up therapeutic discovery pipelines.
Potential impact
If successful, this collaboration could:
-
Shorten the time and cost required to develop new cell and gene therapies.
-
Demonstrate concrete “quantum advantage” in life-science workflows rather than pure simulation benchmarks.
-
Create a repeatable template for other quantum–industry verticals (materials, logistics, finance), where a domain leader teams with a quantum hardware specialist.
Initial projects are planned in Canada and Sweden starting in 2026, signaling that quantum–biotech may become a key application area in the second half of the decade.
